Position in PVLA
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$146,801,794
+$66,949,634 QoQ
Shares Held
960,619
+50.0% QoQ
Ownership
6.67%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#2
of 197 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 86%
Shared 0%
None 14%
Common Shares in PVLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JENNISON ASSOCIATES LLC holds $3,761,825,691 across 45 Biotechnology names. PVLA ranks #4 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,998,530 | $1,489,459,806 | |
| 2 | ARGX |
Argenx SE
|
226,200 | $209,861,574 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
4,481,964 | $158,616,705 | |
| 4 | PVLA |
Palvella Therapeutics, Inc.
This page
|
960,619 | $146,801,794 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
1,151,681 | $141,173,056 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
2,358,587 | $129,722,285 | |
| 7 | IMVT |
Immunovant, Inc.
|
3,310,238 | $127,543,470 | |
| 8 | ARQT |
Arcutis Biotherapeutics, Inc.
|
4,219,058 | $110,623,700 |
All Filings in PVLA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $146,801,794 | 960,619 | Shares | Defined | 2026-08-03 | |
| 2026-06-30 | $146,801,795 | 960,619 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $79,852,160 | 640,611 | Shares | Defined | 2026-05-06 | |
| 2025-12-31 | $40,557,845 | 387,483 | Shares | Defined | 2026-01-30 | |
| 2025-09-30 | $6,702,187 | 106,910 | Shares | Defined | 2025-10-30 | |
| No filing history on record for this holder in this stock. | ||||||